On 14 Apr 2023, the clinical trial evaluating exarafenib (KIN-2787) in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma was reported at the AACR Congress.

Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran, a potential RNAi treatment, designed for addressing hypertension in individuals with significant cardiovascular risk.

This article summarized the latest R&D progress of Zimberelimab, the Mechanism of Action for Zimberelimab, and the drug target R&D trends for Zimberelimab.

Abelacimab 150 mg, a unique Factor XI/XIa inhibitor from Anthos Therapeutics, showcased a 67% decline in significant or notably relevant non-major bleeding versus Rivaroxaban in atrial fibrillation patients.

On 15 Apr 2023, the efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study was reported at the AACR Congress.

This article summarized the latest R&D progress of Satralizumab, the Mechanism of Action for Satralizumab, and the drug target R&D trends for Satralizumab.

Novartis research suggests that remibrutinib, an oral medication, can effectively ease symptoms of chronic spontaneous urticaria as early as the second week of treatment.

On 23 Oct 2023, the updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer was reported at the ESMO Congress.

Ocugen, Inc. declares commencement of Phase 1/2 trial after first administration on patient for OCU410ST - a modifier gene therapy for Stargardt Disease, assessing its safety and effectiveness.

This article summarized the latest R&D progress of Sevelamer Hydrochloride, the Mechanism of Action for Sevelamer Hydrochloride, and the drug target R&D trends for Sevelamer Hydrochloride.

Sana Biotech Reveals FDA Approval of New Drug Application for SC291, a Hypoimmune-modified, Targeting CD19, Allogeneic CAR T Treatment, Targeted for Lupus Nephritis, Extrarenal Lupus, and ANCA-linked Vasculitis Patients.

The disclosure of the clinical trial of Trastuzumab deruxtecan (T-DXd) for the pretreatment of patients (pts) with her2-expressing solid tumors at ESMO 2023 provides the factual basis for subsequent, more in-depth studies.